Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Regulation01:25

Drug Regulation

1.4K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
1.4K
Pharmacovigilance01:19

Pharmacovigilance

825
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
825
Drug Control Governance: Regulatory Bodies and Their Impact01:03

Drug Control Governance: Regulatory Bodies and Their Impact

156
Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with...
156
Clinical Trials: Overview01:11

Clinical Trials: Overview

2.9K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.9K
Drug Nomenclature01:17

Drug Nomenclature

1.7K
During the development of a new pharmaceutical, the manufacturer initially assigns a code name to the drug. Once approved, the drug receives a United States Adopted Name (USAN)—a generic, nonproprietary designation. Upon being listed in the United States Pharmacopeia, this nonproprietary name becomes the drug's official name. Additionally, the manufacturer assigns a proprietary name or trademark, which serves as the brand name under which the drug is marketed. It is worth noting that...
1.7K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

125
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
125

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Seeking HELP beyond the pill: Women's perceptions of informed consent for medication abortion: Mixed methods research.

PloS one·2026
Same author

Tri-specific Humabody CB307 Targeting CD137, Prostate-specific Membrane Antigen, and Human Serum Albumin Whole-body Biodistribution Measured with 89Zr-CB307 PET.

Molecular cancer therapeutics·2026
Same author

A Phase I Dose Escalation and Cohort Expansion Study of CB307, a Trispecific Humabody against PSMA, CD137, and Albumin in Patients with PSMA-Positive Solid Tumors.

Clinical cancer research : an official journal of the American Association for Cancer Research·2025
Same authorSame journal

First Pregnancy Abortion or Natural Pregnancy Loss: A Cohort Study of Mental Health Services Utilization.

Issues in law & medicine·2024
Same author

On the Performance of a Horizontally Mounted ADCP in an Energetic Tidal Environment for Floating Tidal Turbine Applications.

Sensors (Basel, Switzerland)·2024
Same authorSame journal

Misleading Statements About "Life of the Mother" Exceptions in Pro-life Laws Require Correction.

Issues in law & medicine·2024

Related Experiment Video

Updated: Jun 25, 2025

Author Spotlight: Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies
09:30

Author Spotlight: Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies

Published on: March 17, 2023

3.3K

United Kingdom Data Deficiencies Influencing U.S. FDA Decisions.

Ingrid Skop1, Calum Miller2, Kevin Duffy3

  • 1Vice President and Director of Medical Affairs, Charlotte Lozier Institute, 2800 Shirlington Rd, Arlington, Virginia 22206, United States.

Issues in Law & Medicine
|May 21, 2024
PubMed
Summary

The U.S. FDA removed in-person prescribing for mifepristone/misoprostol abortions, increasing risks. This paper examines deficiencies in studies used to justify this telemedicine policy change.

More Related Videos

Scanning Light Scattering Profiler SLPS Based Methodology to Quantitatively Evaluate Forward and Backward Light Scattering from Intraocular Lenses
06:55

Scanning Light Scattering Profiler SLPS Based Methodology to Quantitatively Evaluate Forward and Backward Light Scattering from Intraocular Lenses

Published on: June 6, 2017

7.6K
Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

14.5K

Related Experiment Videos

Last Updated: Jun 25, 2025

Author Spotlight: Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies
09:30

Author Spotlight: Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies

Published on: March 17, 2023

3.3K
Scanning Light Scattering Profiler SLPS Based Methodology to Quantitatively Evaluate Forward and Backward Light Scattering from Intraocular Lenses
06:55

Scanning Light Scattering Profiler SLPS Based Methodology to Quantitatively Evaluate Forward and Backward Light Scattering from Intraocular Lenses

Published on: June 6, 2017

7.6K
Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

14.5K

Area of Science:

  • Reproductive Health
  • Public Health Policy
  • Medical Safety

Background:

  • The U.S. Food and Drug Administration (FDA) has removed Risk Evaluation and Mitigation Strategy (REMS) requirements for mifepristone/misoprostol.
  • This allows for telemedicine prescribing and mail distribution of medical abortion drugs.
  • Previous safeguards included in-person dispensing and specific pre-abortion testing.

Purpose of the Study:

  • To analyze the FDA's justification for removing in-person prescribing requirements for mifepristone/misoprostol.
  • To examine the deficiencies in studies cited by the FDA.
  • To assess the potential increased risks associated with telemedicine-based medical abortions.

Main Methods:

  • Critical review of FDA-justifying studies.
  • Analysis of reported complications and undercounting in cited research.
  • Examination of risks related to gestational age determination, ectopic pregnancy diagnosis, RhoGAM indication, and informed consent.

Main Results:

  • The FDA's justification relies on flawed studies with undercounted complications.
  • Removal of in-person requirements increases risks of inadequate gestational age assessment and missed ectopic pregnancies.
  • Potential for failure to order necessary RhoGAM and obtain adequate informed consent is heightened.

Conclusions:

  • The FDA's removal of in-person prescribing for mifepristone/misoprostol poses significant public health risks.
  • Flawed study data was used to support a policy change that may compromise patient safety.
  • Further scrutiny of the evidence base for reproductive health drug policies is warranted.